Edgewise Therapeutics Has Started Enrollment Of GRAND CANYON, A Global Pivotal Study Of Edg-5506 In Individuals With Becker Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Edgewise Therapeutics has begun enrollment for its global pivotal study, GRAND CANYON, of Edg-5506 in individuals with Becker Muscular Dystrophy. This study is an expansion of the CANYON study, which was over-enrolled with 39 adults and 24 adolescents.
September 26, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edgewise Therapeutics' enrollment for the GRAND CANYON study could potentially lead to positive outcomes for the company if the study yields successful results.
The enrollment for the GRAND CANYON study is a significant step for Edgewise Therapeutics. If the study yields positive results, it could potentially lead to the approval of Edg-5506, which would be beneficial for the company. This could lead to an increase in the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100